

AperTO - Archivio Istituzionale Open Access dell'Università di Torino

**Prevalence of postmenopausal osteoporosis in Italy and validation of decision rules for referring women for bone densitometry.**

**This is the author's manuscript**

*Original Citation:*

*Availability:*

This version is available <http://hdl.handle.net/2318/129837> since

*Published version:*

DOI:10.1007/s00223-013-9699-5

*Terms of use:*

Open Access

Anyone can freely access the full text of works made available as "Open Access". Works made available under a Creative Commons license can be used according to the terms and conditions of said license. Use of all other works requires consent of the right holder (author or publisher) if not exempted from copyright protection by the applicable law.

(Article begins on next page)



# UNIVERSITÀ DEGLI STUDI DI TORINO

***This is an author version of the contribution published on:***

*Questa è la versione dell'autore dell'opera:*

*Prevalence of postmenopausal osteoporosis in Italy and validation of decision rules for referring women for bone densitometry.*

*D'Amelio P, Spertino E, Martino F, Isaia GC.*

*Calcif Tissue Int. 2013 May;92(5):437-43. doi: 10.1007/s00223-013-9699-5.*

***The definitive version is available at:***

*La versione definitiva è disponibile alla URL:*

*[<http://link.springer.com/article/10.1007%2Fs00223-013-9699-5>]*

**Prevalence of post menopausal osteoporosis in Italy and validation of decision rules for referring women for bone densitometry.**

Patrizia D'Amelio, Elena Spertino, Francesca Martino, Giovanni Carlo Isaia.

Geriatrics and Bone Metabolic Unit-Department of Medical Science-University of Torino.

**Running title:** screening tests for osteoporosis.

**Corresponding author and reprint request:**

Patrizia D'Amelio, MD, PhD

Gerontology Section, Department of Medical Sciences, University of Torino, Corso Bramante 88/90, 10126 Torino, Italy.

Tel: +390116335533-Fax: +390116636033

E-mail: [patrizia.damelio@unito.it](mailto:patrizia.damelio@unito.it)

**Conflict of interest:** no disclosures.

**Mini abstract:** This paper reports the prevalence of osteoporosis, osteopenia and fractures in 995 healthy women: osteoporotic were 33.67%, osteopenic 46.63% and 19.7% normal at bone density test. The prevalence of fractures was 21.9%, clinical guidelines used for referring women to bone density test performed poorly.

## **ABSTRACT**

*Purpose.* This paper reports the prevalence of osteoporosis, osteopenia and fractures in a cohort of Italian women randomly recruited amongst the general population and validates the use clinical guidelines in referring women to bone density test.

*Methods.* We enrolled in the study 995 healthy women (age range: 45-92 years). A bone density test at lumbar spine and femur was performed and a questionnaire on osteoporosis risk factors was performed in all the patients.

*Results.* The prevalence of osteoporosis was 33.67%, osteopenia 46.63% whereas 19.7% were normal at bone density test. Osteoporotic women were generally older, thinner with a shorter period of estrogen expositions. The prevalence of fractures was 21.9%, fractured women have a lower bone density, were older with longer post-menopausal period.

Clinical guidelines for referring women to bone density test performed poorly (the best performance was 68%).

*Conclusions.* This is the first study providing data on the prevalence of osteoporosis/osteopenia and of fractures in a cohort of healthy postmenopausal women. Known risk factors influences bone density and risk of fractures.

The role of screening test in detecting women with postmenopausal osteoporosis is far from optimal.

**Key words:** osteoporosis, fracture, risk factors, screening test.

## INTRODUCTION

Primary osteoporosis is a skeletal disease characterized by low bone mass and micro architectural deterioration of bone tissue, with an increased fracture risk. Major osteoporotic fractures are a social and economic burden, in developed countries, the lifetime risk for osteoporotic fractures at the wrist, hip or spine is 30% to 40%, very close to that for coronary heart disease. It has been estimated that, in the year 2000, there were some 9.0 million osteoporotic fractures worldwide [1], in Italy we reported recently a prevalence of major osteoporotic fractures of about 34% in a cohort of 4000 women [2]. The number of postmenopausal women living with osteoporosis was predicted to increase from 1.8 million in 2010 to 2.1 million in 2020 (+16.5%) in the UK, this will be associated with an increase in the number of fractures between 16 and 18% [3].

There is a well established relationship between bone mineral density (BMD) and the ability of bone to withstand trauma, such that 60-70% of the variance in bone strength depends on BMD [4-6]. Fracture risk increases 1.5-3 fold for each standard deviation (SD) fall in BMD [4]; osteoporosis was defined on the basis of bone mineral density (BMD) assessment by the WHO in 1994 [7], so the assessment of this parameter is still a crucial point for the diagnosis of osteoporosis, nevertheless there are poor data in literature about osteoporosis prevalence as diagnosed by bone densitometry [8-12].

Several risk factors, both modifiable or not, are implied in favouring postmenopausal bone loss. Among non-modifiable factors important predictors of bone demineralization are: age, sex, period of amenorrhea [8, 9] and parental history of fracture [10]. Important modifiable factors are: dietary

calcium intake [11-16], low body mass index [8, 17, 18], smoking [19-21], reduced physical activity [22, 23], and high alcohol intake [24, 25], nevertheless their role in determining who should have BMD measurement is yet poorly validated.

The indiscriminate application of bone densitometry to a wide number of women causes an important increase in costs and may produce over treatment. It has been showed that screening post-menopausal osteoporosis is cost effective, but, until now, it is not clear which is the best strategy to screen women at risk for osteoporosis [26].

The evaluation of risk factors is important in predicting bone loss and various algorithms implying the assessment of risk factors have been used to define patients to screen for osteoporosis [27]. We developed a score named AMMEB to screen patients at risk for osteoporosis [28], in this paper we analyse the prevalence of osteoporosis and osteopenia in a cohort of Italian women randomly recruited amongst the general population and validated the use of AMMEB as a reliable tool in prescribing BMD testing.

## **METHODS.**

The study was approved by the "Clinical Study Review Committee" of the San Giovanni Battista Hospital, Torino, and all patients signed an informed consent statement prior to recruitment.

### *Subjects enrollement.*

We enrolled the patients from the general practitioner list, in particular we asked each physician enrolled in the study (32 doctors participates) to send to the centre their patients according to a randomization list sent from the centre.

Each doctor was required to send a number of patients that corresponds to 15% of their cohort of patients, if the adherence was lower than 85% the general practitioner was dropped from the study.

The inclusion criteria were female sex and menopause (defined as absence of menstrual cycle for at least one year).

The exclusion criteria were:

- use of drugs active on bone metabolism as calcium and vitamin D, bisphosphonates, SERMs, PTH (1-84 or 1-34), glucocorticoids, antiepileptics, estrogens, chemotherapies, etc
- illness that influences bone turnover as hyperthyroidism, diabetes, celiac disease, hyperparathyroidism, Cushing disease, cancer, etc.
- mental inability to give the consent
- inability to perform bone densitometry (no consent, obesity, inability to walk, etc).

We enrolled in the study 1030 women, 35 women (3.9%) were dropped because of violation of inclusion/exclusion criteria.

#### *Risk factors for osteoporosis and general health.*

All the patients answered a questionnaire on risk factors for osteoporosis. Age, years since menopause, smoking habits, regular alcohol consumption, weekly exercise, prevalent illnesses and drug consumption were recorded during a personal interview on a questionnaire previously used [28-30]. Routinary physical activity was anamnestically recalled and defined as inferior to half an hour, between half an hour and an hour and more than one hour daily. Smokers were classified as: current (number of cigarettes recorded) or past.

The eating habits were evaluated using a semi-quantitative Food Frequency Questionnaire (FFQ) [29, 30] and weekly calcium intake was recorded.

Presence of fractures was anamnestically recalled, fragility fractures were defined as fractures that occur as result of normal activities, such as a fall from standing height or less.

The weight and height of women wearing light indoor clothing and no shoes were measured to the nearest 0.1 kg and 0.1 cm. Body mass index (BMI) was calculated as usual as weight in kg divided by height in m<sup>2</sup>.

In order to evaluate general health activity of daily living (ADL) and perceived health status were recorded.

#### *Bone density and screening tests.*

Bone mineral density was measured by Dual energy X-ray Absorptiometry (DXA) by means of a Hologic QDR 4500 at lumbar spine and femoral neck.

We considered osteoporotic those patients with a BMD T-score value of -2.5 S.D. or less, normal those patients with a BMD T-score value of -1.0 S.D. and osteopenic those patients with a BMD T-score value between -1.0 to -2.5 S.D., according to WHO [7].

Bone scans were performed by three operators, stability of the DXA scanner was ensured by daily quality control performed by means of a phantom, according to manufacturer instruction. The in vitro coefficient of variation calculated during a year (295 measurement) ranged between 3.1 to 3.3% intra observer, and was 3.0% inter observer.

NOF recommendation, Osteoporosis Risk Assessment Instrument (ORAI), Osteoporosis Self-Assessment Tools (OST) scores and weight criterion have



been applied to this population [31-34]. In order to validate the AMMEB score we have previously proposed [28] we applied also this score (Table 1). Receiver operating characteristic (ROC) curves were plotted for each method to determine the area under the ROC curve (AUROC) at each threshold score [31].

### *Statistics*

The statistics were performed using SPSS 17.0 for Windows and graphs were drawn by Graph Pad PRISM version 3.0.

Osteoporotic, osteopenic and normal patients were compared for age, postmenopausal period, age at menarche, period of estrogen exposition, number of pregnancies and deliveries, BMI, number of cigarettes per day, dietary calcium and alcohol intake by one way ANOVA.

The distribution of categorical variables (smoking habit, family history of fragility fractures before the age of 75; presence and type of fractures were analyzed by  $\chi^2$  test).

NOF guidelines, ORAI, OST score, weight criterion and AMMEB score were applied to our population; ROC curves were plotted for each method to determine the area under the AUROC at each threshold score.

In all the statistical analyses performed the result was considered significant if the p value was equal or lower than 0.05.

## **RESULTS**

A total of 1030 women were sent to the centre by their physicians, of which 995 (96.6%) were enrolled in the study and included in the analyses, the

mean age was not significantly different amongst the women included ( $65\pm 8$ , years) and excluded ( $63\pm 9$ , years) from the study.

The age of included women ranges between 45 and 92 years.

*Prevalence of osteoporosis and osteopenia and patients' characteristic.*

Three hundred and thirty five subjects resulted osteoporotic (33.67%), 464 osteopenic (46.63%) and 196 normal (19.7%). Osteoporotic and osteopenic were generally older, with longer post-menopausal period and shorter period of exposition to estrogens and had lower BMI as compared to normal subjects; calcium and alcohol intake, number of smoked cigarettes, physical activity and familiar history of fractures were not significantly different in the three categories (Table 2).

*Screening tests and bone density.*

All the applied screening tests were significantly different amongst the three categories (Table 3).

The comparison between the AUROCs of the 5 scored applied showed that all the applied scores performed poorly in finding osteoporotic patients (AUROCs ranged between 0.32 to 0.68), the two more performant scores were ORAI and AMMEB scores (Fig.1).

### *Prevalence of fractures and patients' characteristic.*

Nine hundred and thirty six women answer the question on previous fractures, among these 211 reported a fracture (21.9%), there were no significant differences in the incidence of fractures (due to high or low energy trauma) according with different densitometric features (Fig.2 A), but there was significant difference in the site of fracture (Fig.2B). The most frequent fracture site was the wrist (46% of all the fractures).

Fractured patients were on average older, had a longer post-menopausal period and lower femoral density (Table 4).

### *Screening tests and fractures.*

All the screening tests applied except for weight criterion are significantly different in fractured as respect to non fractured patients, nevertheless the comparison between the AUROCs of the 5 scored applied showed that AMMEB and ORAI scores (both 0.55) have the best performance, the other scores performed poorly. NOF score was not applied for the presence of fracture evaluation within the score.

### *ADL and general health.*

There was not a significant difference in perceived health status nor in the level of ADL amongst the different densitometric categories, nor in fractured and non fractured patients (data not shown)

## **DISCUSSION**

Osteoporosis and osteoporotic fractures represent a social and economic burden; several studies suggested that the incidence of osteoporosis is increasing due to the increase in the aging population. It is estimated that about 75 million people in Europe, the United States, and Japan are affected by osteoporosis, and by the year 2050, this number is expected to increase by 240% [35]. Osteoporotic fractures have been seen to affect up to one-third of the postmenopausal women older than 50 yr [36], resulting in considerable mortality, morbidity [37], and cost [38]. The early identification of women at higher risk to develop osteoporosis and hence fragility fractures could reduce the economic and social cost of osteoporosis in terms of mortality and morbidity due to fractures. Hence it is important to find out rapid and low cost screening tests to address women to bone density tests.

Our study was designed to describe the prevalence of osteoporosis, osteopenia and fractures in a cohort of healthy Italian women and to assess whether commonly used screening tests and the one previously proposed by our group could be useful to address women to bone density tests.

Amongst the 995 women enrolled 33.67% were osteoporotic, 46.63% osteopenic and 19.7% normal, these prevalences are very similar to those previously reported by our group [28], whereas osteoporosis and osteopenia are more prevalent in our cohort than in eastern countries [10-12], lifestyle as well as cultural and religious practices may explain this difference. A recent study on Italian women from Pedrazzoni et al [39] showed a lower prevalence of osteoporosis (17%), higher of osteopenia (62%), and similar of normal bone density (21%) as respect to the present study, this discrepancy may be

due to the site of bone scan chosen, we measured both lumbar spine and femoral neck whereas Pedrazzoni and colleagues measured only femoral neck; thus site-specific differences in BMD may explain the different data obtained [40].

Osteoporotic and osteopenic were generally older, with longer post-menopausal period and shorter period of exposition to estrogens and had lower BMI as compared to normal subjects; calcium and alcohol intake, number of smoked cigarettes, physical activity and familiar history of fractures were not significantly different in the three categories.

As respect to our previous study in a smaller cohort [28] we do not find significant difference in the age of menarche amongst the different densitometric categories, nor amongst fractured and non fractured patients, nevertheless we find a significant difference in the years of exposition to estrogens.

The prevalence of fractures in our cohort was 21.9%, we do not find a higher prevalence of fractures in women diagnosed as osteoporotic/osteopenic according with standard reference values, even though fracture patients have significantly lower values of femoral BMD, this observation confirms the importance of a decrease in BMD together with the presence of other risk factors as age and post menopausal period.

As regards the fracture site there was a significant difference according with the presence/absence of osteoporosis/osteopenia, in patients with low BMD it is more likely to find typical osteoporotic fractures as wrist, lumbar spine and proximal femur fractures, whereas in osteopenic and normal subjects it is

more likely to find fractures in other sites. These fractures are probably due to higher impact energy. The only risk factors significantly different between fractured and non fractured patients were age and post-menopausal period. The main study pitfall is the probable underestimation of vertebral fractures, as we detect only clinical fractures (by anamnesis) and do not performed spine X-ray. It is known that only one fourth to one third of incident radiographically identified vertebral fractures are clinically diagnosed [41], hence it is reasonable to suppose an under estimation of vertebral fracture in our cohort.

The use of the clinic guidelines to address women to bone density test performed poorly in detecting osteoporotic women AUROCs ranged between 0.32 and 0.68, however the better scores were ORAI and AMMEB (AUROC 0.68 and 0.63 respectively). The performance of these score in detecting fractures is even poorer.

In conclusion this study provides data on the prevalence of osteoporosis/osteopenia and of fractures in a cohort of healthy postmenopausal women. We evaluate the role of risk factors in determining bone density and risk of fractures. We also evaluate the role of screening test in detecting women with postmenopausal osteoporosis. Even though the performance of the screening tests it is far from optimal, the use of clinical decision rule to individuate patients at higher risk for bone loss may be cost effective [26, 34]

**Acknowledgements:** The study was funded by an unrestricted grant by Fondazione San Paolo and Fondazione Osteoporosi Piemonte.

The following physicians participate in the recruitment of the patients:

Giuseppe Aceto, Daria Aicardi, Beatrice Amosso, Daniela Armando, Rosaria Attardo, Emanuele Barbuto, Sabina Bianchi, Gian Carlo Bulgarelli, Francesca Capobianco, Francesco Castronuovo, Roberto Cernigliaro, Enrico D'Alessandro, Elodia Di Iorio, Maria Teresa Dionisotti, Gabriella Elia, Maurizio Fassone, Salvatore Freni, Daniela Gaido Marco Giovandone, Giorgio Gjerga, Massimo Guatteo, Benedetto Iurato, Luisella Maglietta, Lino Milan, Palmira Oggero, Silvana Pelissero, Giorgio Rigamonti, Michela Seren Rosso, Maria Clara Serra, Giuseppe Tafuri, Tiziana Torchio, Marzio Uberti.



## REFERENCES

- 1 Johnell O, Kanis JA (2006) An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. *Osteoporos Int* 17:1726-1733.
- 2 Isaia GC, Braga V, Minisola S, Bianchi G, Del Puente A, Di Matteo L, Pagano Mariano G, Latte VM, D'Amico F, Bonali C, D'Amelio P (2011) Clinical characteristics and incidence of first fracture in a consecutive sample of postmenopausal women attending osteoporosis centers: The PROTEO-1 study. *J Endocrinol Invest* 34:534-540.
- 3 Gauthier A, Kanis JA, Jiang Y, Martin M, Compston JE, Borgstrom F, Cooper C, McCloskey EV (2011) Epidemiological burden of postmenopausal osteoporosis in the UK from 2010 to 2021: estimations from a disease model. *Arch Osteoporos* 6:179-188.
- 4 Ammann P, Rizzoli R (2003) Bone strength and its determinants. *Osteoporos Int* 14 Suppl 3:S13-18.
- 5 D'Amelio P, Rossi P, Isaia G, Lollino N, Castoldi F, Girardo M, Dettoni F, Sattin F, Delise M, Bignardi C (2008) Bone mineral density and Singh index predict bone mechanical properties of human femur. *Connect Tissue Res* 49:99-104.
- 6 Brianza SZ, D'Amelio P, Pugno N, Delise M, Bignardi C, Isaia G (2007) Allometric scaling and biomechanical behavior of the bone tissue: an experimental intraspecific investigation. *Bone* 40:1635-1642.
- 7 Kanis JA (1994) Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: synopsis of a WHO report. WHO Study Group. *Osteoporos Int* 4:368-381.

- 8 Mohamed EI, Tarantino U, Promenzio L, De Lorenzo A (2003) Predicting bone mineral density of postmenopausal healthy and cirrhotic Italian women using age and body mass index. *Acta Diabetol* 40 Suppl 1:S23-28.
- 9 Kanis JA, Johnell O (2005) Requirements for DXA for the management of osteoporosis in Europe. *Osteoporos Int* 16:229-238.
- 10 Kanis JA, Johansson H, Oden A, Johnell O, De Laet C, Eisman JA, McCloskey EV, Mellstrom D, Melton LJ, 3rd, Pols HA, Reeve J, Silman AJ, Tenenhouse A (2004) A family history of fracture and fracture risk: a meta-analysis. *Bone* 35:1029-1037.
- 11 Karasik D, Cupples LA, Hannan MT, Kiel DP (2003) Age, gender, and body mass effects on quantitative trait loci for bone mineral density: the Framingham Study. *Bone* 33:308-316.
- 12 Shea B, Wells G, Cranney A, Zytaruk N, Robinson V, Griffith L, Hamel C, Ortiz Z, Peterson J, Adachi J, Tugwell P, Guyatt G (2004) Calcium supplementation on bone loss in postmenopausal women. *Cochrane Database Syst Rev* CD004526.
- 13 Matkovic V, Goel PK, Badenhop-Stevens NE, Landoll JD, Li B, Ilich JZ, Skugor M, Nagode LA, Mobley SL, Ha EJ, Hangartner TN, Clairmont A (2005) Calcium supplementation and bone mineral density in females from childhood to young adulthood: a randomized controlled trial. *Am J Clin Nutr* 81:175-188.
- 14 Matkovic V, Landoll JD, Badenhop-Stevens NE, Ha EY, Crncevic-Orlic Z, Li B, Goel P (2004) Nutrition influences skeletal development from childhood to adulthood: a study of hip, spine, and forearm in adolescent females. *J Nutr* 134:701S-705S.

- 15 Tussing L, Chapman-Novakofski K (2005) Osteoporosis prevention education: Behavior theories and calcium intake. *J Am Diet Assoc* 105:92-97.
- 16 Kanis JA, Johansson H, Oden A, De Laet C, Johnell O, Eisman JA, McCloskey E, Mellstrom D, Pols H, Reeve J, Silman A, Tenenhouse A (2005) A meta-analysis of milk intake and fracture risk: low utility for case finding. *Osteoporos Int* 16:799-804.
- 17 Prentice A (2004) Diet, nutrition and the prevention of osteoporosis. *Public Health Nutr* 7:227-243.
- 18 Knoke JD, Barrett-Connor E (2003) Weight loss: a determinant of hip bone loss in older men and women. The Rancho Bernardo Study. *Am J Epidemiol* 158:1132-1138.
- 19 Broussard DL, Magnus JH (2004) Risk assessment and screening for low bone mineral density in a multi-ethnic population of women and men: does one approach fit all? *Osteoporos Int* 15:349-360.
- 20 Liu X, Kohyama T, Kobayashi T, Abe S, Kim HJ, Reed EC, Rennard SI (2003) Cigarette smoke extract inhibits chemotaxis and collagen gel contraction mediated by human bone marrow osteoprogenitor cells and osteoblast-like cells. *Osteoporos Int* 14:235-242.
- 21 Lee LL, Lee JS, Waldman SD, Casper RF, Grynblas MD (2002) Polycyclic aromatic hydrocarbons present in cigarette smoke cause bone loss in an ovariectomized rat model. *Bone* 30:917-923.
- 22 Ford MA, Bass MA, Turner LW, Mauromoustakos A, Graves BS (2004) Past and recent physical activity and bone mineral density in college-aged women. *J Strength Cond Res* 18:405-409.

23 Asikainen TM, Kukkonen-Harjula K, Miilunpalo S (2004) Exercise for health for early postmenopausal women: a systematic review of randomised controlled trials. *Sports Med* 34:753-778.

24 Kim MJ, Shim MS, Kim MK, Lee Y, Shin YG, Chung CH, Kwon SO (2003) Effect of chronic alcohol ingestion on bone mineral density in males without liver cirrhosis. *Korean J Intern Med* 18:174-180.

25 Kanis JA, Johansson H, Johnell O, Oden A, De Laet C, Eisman JA, Pols H, Tenenhouse A (2005) Alcohol intake as a risk factor for fracture. *Osteoporos Int* 16:737-742.

26 Nayak S, Roberts MS, Greenspan SL (2011) Cost-effectiveness of different screening strategies for osteoporosis in postmenopausal women. *Ann Intern Med* 155:751-761.

27 McCloskey E, Johansson H, Oden A, Kanis JA (2012) Fracture risk assessment. *Clin Biochem* 2012:554-560.

28 D'Amelio P, Tamone C, Pluviano F, Di Stefano M, Isaia G (2005) Effects of lifestyle and risk factors on bone mineral density in a cohort of Italian women: suggestion for a new decision rule. *Calcif Tissue Int* 77:72-78.

29 Adami S, Giannini S, Giorgino R, Isaia G, Maggi S, Sinigaglia L, Filipponi P, Crepaldi G, Di Munno O (2003) The effect of age, weight, and lifestyle factors on calcaneal quantitative ultrasound: the ESOPO study. *Osteoporos Int* 14:198-207.

30 Adami S, Braga V, Zamboni M, Gatti D, Rossini M, Bakri J, Battaglia E (2004) Relationship between lipids and bone mass in 2 cohorts of healthy women and men. *Calcif Tissue Int* 74:136-142.

- 31 Cadarette SM, Jaglal SB, Kreiger N, McIsaac WJ, Darlington GA, Tu JV (2000) Development and validation of the Osteoporosis Risk Assessment Instrument to facilitate selection of women for bone densitometry. *Cmaj* 162:1289-1294.
- 32 Cadarette SM, Jaglal SB, Murray TM, McIsaac WJ, Joseph L, Brown JP (2001) Evaluation of decision rules for referring women for bone densitometry by dual-energy x-ray absorptiometry. *Jama* 286:57-63.
- 33 Cadarette SM, McIsaac WJ, Hawker GA, Jaakkimainen L, Culbert A, Zarifa G, Ola E, Jaglal SB (2004) The validity of decision rules for selecting women with primary osteoporosis for bone mineral density testing. *Osteoporos Int* 15:361-366.
- 34 Richy F, Ethgen O, Bruyere O, Mawet A, Reginster JY (2004) Primary prevention of osteoporosis: mass screening scenario or prescreening with questionnaires? An economic perspective. *J Bone Miner Res* 19:1955-1960.
- 35 Gullberg B, Johnell O, Kanis JA (1997) World-wide projections for hip fracture. *Osteoporos Int* 7:407-413.
- 36 Rogmark C, Johnell O (2005) Orthopaedic treatment of displaced femoral neck fractures in elderly patients. *Disabil Rehabil* 27:1143-1149.
- 37 Cauley JA, Thompson DE, Ensrud KC, Scott JC, Black D (2000) Risk of mortality following clinical fractures. *Osteoporos Int* 11:556-561.
- 38 Burge R, Dawson-Hughes B, Solomon DH, Wong JB, King A, Tosteson A (2007) Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025. *J Bone Miner Res* 22:465-475.
- 39 Pedrazzoni M, Girasole G, Giusti A, Barone A, Pioli G, Passeri G, Palummeri E, Bianchi G (2011) Assessment of the 10-year risk of fracture in

Italian postmenopausal women using FRAX®: a north Italian multicenter study. *J Endocrinol Invest* 34:e386-391.

40 Chantler S, Dickie K, Goedecke JH, Levitt NS, Lambert EV, Evans J, Joffe Y, Micklesfield LK (2012) Site-specific differences in bone mineral density in black and white premenopausal South African women. *Osteoporos Int* 23:533-542.

41 Fink HA, Milavetz DL, Palermo L, Nevitt MC, Cauley JA, Genant HK, Black DM, Ensrud KE; Fracture Intervention Trial Research Group (2005) What proportion of incident radiographic vertebral deformities is clinically diagnosed and vice versa? *J Bone Miner Res* 20:1216-1222.

**TABLES.**

**Table 1.** Clinical decision rules for bone mineral density testing among postmenopausal women.

<b>Guideline/rule</b>	<b>Selection cut point</b>	<b>Scoring system</b>
<b>National Osteoporosis Foundation (NOF)</b>	Score equal or more than 1	1 point each for: Age > or =65 Weight < 57.6 Minimal trauma fracture > 40 years Family history of fractures Currently cigarette smoking
<b>Osteoporosis Self-Assessment Tools (OST)</b>	<2	Equation = 0.2x (weight in Kg x – age in years) truncated to yield an integer Age (years): 15 if 75+, 9 if 65-74, 5 if 55-64, 0 if 5 equal or lower than 55
<b>Osteoporosis Risk Assessment Instrument (ORAI)</b>	>8	Weight (Kg): 9 if <60, 3 if 60-69.9 Estrogen: 2 if not current taking
<b>Weight criterion</b>	Body weight < 70 Kg	High risk if body weight < 70 Kg
<b>Age, years after Menopause, age at MEnarche, BMI (AMMEB)</b>	Score equal or more than 10	Age (years): 15 if 75+, 9 if 65-74, 5 if 55-64, 0 if equal or lower than 55 BMI: 6 if <20, 2 if 20-23, 1 if 24-26, 0 if >26 Age at menarche: 0 if <11, 1 if 11-13, 6 if >13 Postmenopausal period: 5 if >16, 3 if 12-16, 1 if 5-11, 0 if <5.

**Table 2.** Subjects characteristics in the three densitometric categories. Numerical variables are expressed as mean and SD, p values were obtained by one way ANOVA; categorical variables are expressed as percentage, p values were obtained by  $\chi^2$  Test.

	<b>Osteoporotic (335)</b>	<b>Normal (196)</b>	<b>Osteopenic (464)</b>	<b>p</b>
<b>Age (yrs)</b>	67±9	62±7	64±8	0.000
<b>Post menopausal period (yrs)</b>	18±10	11±8	15±9	0.000
<b>Menarche (yrs)</b>	13±2	13±1	13±2	NS
<b>Period of exposition to estrogens (yrs)</b>	36±5	38±5	36±5	0.002
<b>BMI</b>	23.8±4.4	27.3±5	25.9±4.8	0.000
<b>Age at menarche (yrs)</b>	13±2	13±1	13±2	NS
<b>Calcium intake (mg/day)</b>	902.9±482.7	1544.1±620.3	2529.1±1593	NS
<b>Cigarettes/day</b>	12±6	12±5	11±6	NS
<b>Alcohol (gr/day)</b>	8.68±0.6	8.9±0.8	7.95±0.52	NS
<b>Familiar history of fractures (%)</b>	41.7	33.1	43.12	NS
<b>Active smokers (%)</b>	14.1	16.9	14.2	NS
<b>Sun exposition (%)</b>	70.2	74	76	NS
<b>Physical activity inferior to 30'/day</b>	28	18.3	20.1	NS
<b>Physical activity between 30' and 1 hour day</b>	40.4	45	42.5	NS
<b>Physical activity between 1 and 2 hours day</b>	21.3	25.7	24.5	NS
<b>Physical activity higher than 2 hours day</b>	10.3	11	12.9	NS



**Table 3.** Clinical decision rules for bone mineral density testing among the three densitometric categories. Variables are expressed as mean and SD, p values were obtained by one way ANOVA and considered significant if lower than 0.05.

	<b>Osteoporotic</b>	<b>Normal</b>	<b>Osteopenic</b>	<b>P</b>
	(335)	(196)	(464)	
<b>NOF guidelines</b>	1.76±1.1	1.12±0.9	1.5±0.98	0.000
<b>ORAI score</b>	18.48±5.8	12.96±4.87	15.6±5.37	0.000
<b>OST score</b>	-1.99±4.01	0.96±3.8	-0.44±3.99	0.000
<b>Weight criterion</b>	60.3±9.7	70.11±11	66.12±11.4	0.000
<b>AMMEB score</b>	15.95±7.38	10.92±6.28	13.37±6.5	0.000


**Table 4.** Subjects characteristics amongst fractured and non fractured.

Numerical variables are expressed as mean and SD, p values were obtained by one way ANOVA; categorical variables are expressed as percentage, p values were obtained by  $\chi^2$  Test

	<b>Non fractured (725)</b>	<b>Fractured (211)</b>	<b>p</b>
<b>Age (yrs)</b>	64±8	66±9	0.001
<b>Post menopausal period (yrs)</b>	14±9	17±10	0.003
<b>Period of exposition to estrogens (yrs)</b>	36±5	38±5	NS
<b>BMD total femur (g/cm<sup>2</sup>)</b>	0.782±0.128	0.737±0.119	0.001
<b>Age at menarche (yrs)</b>	13±2	13±1	NS
<b>BMD femoral neck (g/cm<sup>2</sup>)</b>	0.650±0.106	0.610±0.101	0.000
<b>BMI</b>	25.6±4.7	25.3±5	NS
<b>Calcium intake (mg/day)</b>	2102.3±1037.4	902.7±419.8	NS
<b>Cigarettes/day</b>	12±6	12±6	NS
<b>Alcohol (gr/day)</b>	8.13±10.5	9.3±11.8	NS
<b>Familiar history of fractures (%)</b>	39.8	46.11	NS
<b>Active smokers (%)</b>	16.3	13.1	NS
<b>Sun exposition (%)</b>	74	73	NS
<b>Physical activity inferior to 30'/day</b>	22.1	23.5	NS
<b>Physical activity between 30' and 1 hour day</b>	43.3	39	NS
<b>Physical activity between 1 and 2 hours day</b>	22.6	28.6	NS
<b>Physical activity higher than 2 hours day</b>	12	8.9	NS

**Figure legends.**

**Figure 1.** ROC curves for the clinical decision rules for bone mineral density testing; AUROCs are indicated in the table.



**Figure 2.** Graphs shows the prevalence of fractures as distributed according to densitometric test.

**Panel A.** Prevalence of fractures in the three categories according to the energy of the impact sustained.

**Panel B.** Prevalence of fractures in the three categories according to the site of fractures. P value is calculated with  $\chi^2$  test.

